Skip to main content
Top
Published in: Diabetology International 1/2021

01-01-2021 | Pyelonephritis | Case Report

A case of an elderly patient with insulin-dependent diabetes and dementia receiving one basal insulin plus one bolus insulin injections a day for 6 months

Authors: Taichi Minami, Jun Shirakawa, Akiko Kameda, Yoichi Suzuki, Kaoru Watanabe, Taku Yamada, Hiroko Hiiragi, Soichiro Takeda, Mayuko Takahashi, Yasuo Terauchi

Published in: Diabetology International | Issue 1/2021

Login to get access

Abstract

Multiple daily injections of insulin, referred to basal–bolus regimen, are generally essential in achieving glycemic control and preventing ketosis in insulin-dependent diabetes, such as type 1 diabetes (T1D). A 75-year-old man with T1D receiving basal–bolus insulin therapy exhibited symptoms of dementia after hospitalization due to pyelonephritis and failed to continue insulin self-injection. Given that his social and familial circumstances allowed insulin injection once a day during the morning, bolus insulin injections needed to be discontinued. Ketonuria was observed the day following discontinuation of bolus insulin. Although increasing the basal insulin dose (degludec) from 10 to 15 units improved ketonuria, his preprandial glucose levels increased to ≥ 500 mg/dL before lunch and ≥ 400 mg/dL before dinner. Hence, another bolus insulin injection was simultaneously added to the basal insulin dose before breakfast, which, subsequently, decreased his preprandial glucose levels to ≤ 220 mg/dL before lunch and ≤ 350 mg/dL before dinner. For half a year after discharge, ketonuria or hypoglycemia had not been detected. After 6 months, he was able to restart intensive insulin therapy with familial support. Hence, in cases where elderly patients with diabetes exhibit symptoms of dementia and can receive insulin injection once a day due to their social circumstances, short-term one basal plus one bolus insulin injections a day might be considered to prevent life-threatening diabetes complications among those who are insulin-dependent.
Literature
1.
go back to reference Minami T, Yamada M, Furuta R, Kamata K, Katsuragawa S, et al. Predicting the ability of elderly diabetes patients to acquire the insulin self-injection technique based on the number of animal names recalled. J Diabetes Investig. 2018;9:623–8.CrossRef Minami T, Yamada M, Furuta R, Kamata K, Katsuragawa S, et al. Predicting the ability of elderly diabetes patients to acquire the insulin self-injection technique based on the number of animal names recalled. J Diabetes Investig. 2018;9:623–8.CrossRef
2.
go back to reference Haneda M, Noda M, Origasa H, Noto H, Yabe D, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018;9:657–97.CrossRef Haneda M, Noda M, Origasa H, Noto H, Yabe D, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018;9:657–97.CrossRef
3.
go back to reference Sekita A, Ninomiya T, Tanizaki Y, Doi Y, Hata J, et al. Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: the Hisayama Study. Acta Psychiatr Scand. 2010;122:319–25.CrossRef Sekita A, Ninomiya T, Tanizaki Y, Doi Y, Hata J, et al. Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: the Hisayama Study. Acta Psychiatr Scand. 2010;122:319–25.CrossRef
4.
go back to reference Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173:1300–6.CrossRef Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173:1300–6.CrossRef
6.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
7.
go back to reference Paraskevaidi M, Martin-Hirsch PL, Martin FL. Progress and challenges in the diagnosis of dementia: a critical review. ACS Chem Neurosci. 2018;9:446–61.CrossRef Paraskevaidi M, Martin-Hirsch PL, Martin FL. Progress and challenges in the diagnosis of dementia: a critical review. ACS Chem Neurosci. 2018;9:446–61.CrossRef
8.
go back to reference Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. Committee Report: glycemic targets for elderly patients with diabetes. J Diabetes Investig. 2017;8:126–128. Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. Committee Report: glycemic targets for elderly patients with diabetes. J Diabetes Investig. 2017;8:126–128.
9.
go back to reference Toyoshima K, Araki A, Tamura Y, Iritani O, Ogawa S, et al. Development of the dementia assessment sheet for community-based integrated care system 8-items, a short version of the dementia assessment sheet for community-based integrated care system 21-items, for the assessment of cognitive and daily functions. Geriatr Gerontol Int. 2018;18:1458–62.CrossRef Toyoshima K, Araki A, Tamura Y, Iritani O, Ogawa S, et al. Development of the dementia assessment sheet for community-based integrated care system 8-items, a short version of the dementia assessment sheet for community-based integrated care system 21-items, for the assessment of cognitive and daily functions. Geriatr Gerontol Int. 2018;18:1458–62.CrossRef
10.
go back to reference Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82.CrossRef Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82.CrossRef
11.
go back to reference Li FR, Zhang XR, Zhong WF, Li ZH, Gao X, et al. Glycated hemoglobin and all-cause and cause-specific mortality among adults with and without diabetes. J Clin Endocrinol Metab. 2019;104:3345–54.CrossRef Li FR, Zhang XR, Zhong WF, Li ZH, Gao X, et al. Glycated hemoglobin and all-cause and cause-specific mortality among adults with and without diabetes. J Clin Endocrinol Metab. 2019;104:3345–54.CrossRef
12.
go back to reference Shinagawa S, Honda K, Kashibayashi T, Shigenobu K, Nakayama K, et al. Classifying eating-related problems among institutionalized people with dementia. Psychiatry Clin Neurosci. 2016;70:175–81.CrossRef Shinagawa S, Honda K, Kashibayashi T, Shigenobu K, Nakayama K, et al. Classifying eating-related problems among institutionalized people with dementia. Psychiatry Clin Neurosci. 2016;70:175–81.CrossRef
13.
go back to reference Monnier L, Colette C, Rabasa-Lhoret R, Lapinski H, Caubel C, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care. 2002;25:737–41.CrossRef Monnier L, Colette C, Rabasa-Lhoret R, Lapinski H, Caubel C, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care. 2002;25:737–41.CrossRef
14.
go back to reference Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2:30–7.CrossRef Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2:30–7.CrossRef
15.
go back to reference Philis-Tsimikas A, Astamirova K, Gupta Y, Haggag A, Roula D, et al. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;147:157–65.CrossRef Philis-Tsimikas A, Astamirova K, Gupta Y, Haggag A, Roula D, et al. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;147:157–65.CrossRef
16.
go back to reference Ståhl CH, Lind M, Svensson AM, Gudbjörnsdottir S, Mårtensson A, et al. Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med. 2017;281:261–72.CrossRef Ståhl CH, Lind M, Svensson AM, Gudbjörnsdottir S, Mårtensson A, et al. Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med. 2017;281:261–72.CrossRef
17.
go back to reference Lacy ME, Gilsanz P, Karter AJ, Quesenberry CP, Pletcher MJ, et al. long-term glycemic control and dementia risk in type 1 Diabetes. Diabetes Care. 2018;41:2339–455.CrossRef Lacy ME, Gilsanz P, Karter AJ, Quesenberry CP, Pletcher MJ, et al. long-term glycemic control and dementia risk in type 1 Diabetes. Diabetes Care. 2018;41:2339–455.CrossRef
18.
go back to reference Mori H, Kuroda A, Araki M, Suzuki R, Taniguchi S, et al. Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. J Diabetes Investig. 2017;8:377–82.CrossRef Mori H, Kuroda A, Araki M, Suzuki R, Taniguchi S, et al. Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. J Diabetes Investig. 2017;8:377–82.CrossRef
Metadata
Title
A case of an elderly patient with insulin-dependent diabetes and dementia receiving one basal insulin plus one bolus insulin injections a day for 6 months
Authors
Taichi Minami
Jun Shirakawa
Akiko Kameda
Yoichi Suzuki
Kaoru Watanabe
Taku Yamada
Hiroko Hiiragi
Soichiro Takeda
Mayuko Takahashi
Yasuo Terauchi
Publication date
01-01-2021
Publisher
Springer Singapore
Published in
Diabetology International / Issue 1/2021
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-020-00452-8

Other articles of this Issue 1/2021

Diabetology International 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine